A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

作者：Oh Sung Yong; Kim Won Seog; Kim Jin Seok; Chae Yee Soo; Lee Gyeong Won; Eom Hyeon Seok; Ryoo Hun Mo; Lee Suee; Kim Seok Jin; Yoon Dok Hyun; Won Jong Ho; Hong Junshik; Park Jinny; Lee Sang Min; Hong Jung Yong; Park Eunkyung; Kim Hyo Jung; Yang Deok Hwan; Kim Hyo Jin; Suh Cheolwon^*

来源：Leukemia and Lymphoma, 2016, 57(6): 1406-1412.

DOI：10.3109/10428194.2015.1099650

• Oxaliplatin
• prednisone
• relapse
• refractory
• marginal zone lymphoma

Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130mg/m(2) on day 1 and prednisone 100mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range=27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate=64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI=2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).

• 出版日期2016-6